TFPI2 and colorectal carcinoma: Furthermore, TFPI2 methylation in fecal samples from stage I to III CRC patients has shown promise as a biomarker for early CRC detection, with sensitivity ranging from 76% to 89% and specificity ranging from 79% to 93% [24–26].